Ifetroban (sodium)

Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research[1][2][3][4].

Product Specifications

CAS Number

[156715-37-6]

Product Name Alternative

BMS-180291 (sodium)

UNSPSC

12352005

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Endocrinology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ifetroban-sodium.html

Purity

99.83

Solubility

DMSO : 130 mg/mL (ultrasonic)

Smiles

O=C(O[Na])CCC(C=CC=C1)=C1C[C@@H]2[C@H](C3=NC(C(NCCCCC)=O)=CO3)[C@@H]4O[C@H]2CC4

Molecular Formula

C25H31N2NaO5

Molecular Weight

462.51

References & Citations

[1]Johnson RA, et al. Effect of ifetroban, a thromboxane A2 receptor antagonist, in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens. 1996 Feb;18 (2) :171-88. |[2]Werfel TA, et al. Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study. Mol Cancer Ther. 2020 Dec;19 (12) :2454-2464. |[3]Schumacher WA, et al. Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys. Prostaglandins. 1992 Nov;44 (5) :389-97. |[4]Rosenfeld L, et al. Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist. Cardiovasc Drug Rev. 2001 Summer;19 (2) :97-115.